21734-85-0

Basic information

• Product Name: 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE
• Synonyms: 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE;5-Chlor-3-methyl-[1,2,4]thiadiazol;1,2,4-Thiadiazole, 5-chloro-3-methyl-
• CAS NO: 21734-85-0
• Molecular Formula: C₃H₃ClN₂S
• Molecular Weight: 134.59
• Mol File: 21734-85-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 221.475 °C at 760 mmHg
• Flash Point: 87.745 °C
• Appearance: /
• Density: 1.438 g/cm³
• Vapor Pressure: 0.159mmHg at 25°C
• Refractive Index: 1.566
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.36±0.10(Predicted)
• CAS DataBase Reference: 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE(21734-85-0)
• EPA Substance Registry System: 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE(21734-85-0)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• Hazardous Substances Data: 21734-85-0(Hazardous Substances Data)

Usage

General Description

5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE is a chemical compound that belongs to the thiadiazole family. It is a white to light yellow crystalline powder with a molecular formula of C4H3ClN2S. 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE is primarily used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It possesses antimicrobial and antifungal properties, making it useful in the production of pesticides and antiseptics. Additionally, it has potential application in the development of new drugs for the treatment of various diseases. However, it should be handled with care and in accordance with proper safety protocols due to its potential health hazards.

InChI:InChI=1/C3H3ClN2S/c1-2-5-3(4)7-6-2/h1H3

Upstream product

• 75-09-2 dichloromethane 
• 623-11-0 1-methyl-4-nitrosobenzene 
• 124-42-5 acetamidine hydrochloride 
• 594-42-3 chlorothio-trichloro-methane 
• 143-37-3 acetamidine 
• 20846-52-0 2-chloro-acetamidine 
• 75-70-7 trichloromethyl mercaptan 

Downstream Products

• 36988-21-3 3-methyl-4H-[1,2,4]thiadiazole-5-thione 
• 35550-13-1 5-Methylamino-3-methyl-1,2,4-thiodiazol 
• 21735-09-1 3-methyl-5-(4-nitro-benzenesulfonyl)-[1,2,4]thiadiazole 
• 21735-11-5 N-[4-(3-methyl-[1,2,4]thiadiazole-5-sulfonyl)-phenyl]-acetamide 
• 17467-17-3 cyclohexyl-(3-methyl-[1,2,4]thiadiazol-5-yl)-amine 
• 17467-19-5 N-(4-chlorophenyl)-3-methyl-1,2,4-thiadiazol-5-amine 
• 17467-18-4 3-methyl-N-phenyl-1,2,4-thiadiazol-5-amine 
• 17467-37-7 (3-chloro-phenyl)-(3-methyl-[1,2,4]thiadiazol-5-yl)-amine 
• 17467-36-6 (2-chloro-phenyl)-(3-methyl-[1,2,4]thiadiazol-5-yl)-amine 
• 21735-14-8 4-acetylamino-N-(3-methyl-[1,2,4]thiadiazol-5-yl)-benzenesulfonamide 
• 90920-64-2 4-(3-methyl-[1,2,4]thiadiazol-5-ylamino)-benzonitrile 
• 38362-20-8 5-Hydrazino-3-methyl-1,2,4-thiadiazol 
• 17467-35-5 3-methyl-1,2,4-thiadiazol-5-amine 
• 37864-85-0 3-Methyl-5-methylsulfonyl-1,2,4-thiadiazol 

Relevant articles and documents

PIPERIDINE DERIVATIVES

The invention relates to compounds of formula (I). Hetaryl I is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; hetaryl II is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N, or is a two membered ring system containing 1 to 4 heteroatoms selected from S, O or N, wherein at least one ring is aromatic in nature; R1 is lower alkyl, lower alkoxy, lower alkyl substituted by halogen, or halogen; R2 is halogen, lower alkyl, lower alkoxy, hydroxy, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy or benzo[1,3]dioxolyl, or is -(CHR)p-phenyl, optionally substituted by halogen, lower alkyl, lower alkoxy, S(O)2 -1ower alkyl, cyano, nitro, lower alkoxy substituted by halogen, dimethylamino, -(CH2)P-NHC(O)O-Iower alkyl, or lower alkyl substituted by halogen, and R is hydrogen, halogen, hydroxy or lower alkoxy, or is cycloalkenyl or cycloalkyl, optionally substituted by hydroxy or lower alkyl substituted by halogen, or is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N, which is optionally substituted by halogen, lower alkyl, lower alkoxy or dimethylamino, or is O-phenyl, optionally substituted by halogen, or is heterocycloalkyl, optionally substituted by halogen, hydroxy, lower alkyl substituted by halogen or C(O)O-lower alkyl; R3 is hydrogen, lower alkyl, cyano or phenyl; R4 is lower alkoxy, lower alkyl or halogen; p is 0 or 1; n is 0, 1 or 2; if n is 2 then R4 may be the same or different; m is 0, 1 or 2; if m is 2 then R1 may be the same or different; o is 0, 1, 2 or 3, if o is 2 or 3 then R2 may be the same or different; or to pharmaceutically active acid addition salts thereof. The compounds of formula (I) are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of beta- amyloid in the brain, in particular Alzheimer?s disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome

HISTONE DEACETYLASE INHIBITORS

The present invention provides histone deacetylase inhibitors of general formula (I), a process for the preparation of such compounds and uses of the compounds in medicine, especially in the treatment of cancers: in which R1 is an optionally su

SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarnic receptors of formula (I). The present invention also provides impositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.